Stemcell technologies INC:1109892 [21-001267] - these kits are required for isolation of different human primary immune cells (B cells, NK, neutrophils, monocytes, CD4 T cells, CD8 T cells) from…
Ended Awarded Last action
- Contract number
- 75N92B21F00001
- Awardee
-
Stemcell Technologies Inc. UEI ELPMWCGFK518 Part of Stemcell Tecnologies
- Awarding agency
-
National Insititue of Arthritis and Musculoskeletal and Skin Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $11,315
Award facts
- Contract value 100% obligated
- $11,314.50 Current and potential, with all options
- Completion date
- Current and potential, with all options
- NAICS code
- 541380 Testing Laboratories and Services
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Competed under SAP · 3 offers Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Burien, WA 98168, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$308 | |
| Original award | $11,623 |
About this award
The National Institute of Arthritis and Musculoskeletal and Skin Diseases issued a BPA call to Stemcell Technologies Inc. on May 3, 2021, valued at $11,314.50 for cell isolation kits. The call was issued under a $10 million Blanket Purchase Agreement with the National Institutes of Health Office of Logistics and Acquisition Operations, running through December 31, 2026. The kits support isolation of human primary immune cells—B cells, NK cells, neutrophils, monocytes, CD4 T cells, and CD8 T cells—from patients enrolled in a clinical study. Performance is at Burien, Washington, with ultimate completion on May 3, 2021. The call carries no set-aside designation. Pricing is firm fixed price.
Description
Stemcell technologies INC:1109892 [21-001267] - these kits are required for isolation of different human primary immune cells (B cells, NK, neutrophils, monocytes, CD4 T cells, CD8 T cells) from patients enrolled in our clinical study
Quick answers
Who was awarded contract 75N92B21F00001?
75N92B21F00001 was awarded to Stemcell Technologies Inc. by National Insititue of Arthritis and Musculoskeletal and Skin Diseases (National Institutes of Health) on May 3, 2021.
How much is contract 75N92B21F00001 worth?
The government has obligated $11,315 on 75N92B21F00001.
Is contract 75N92B21F00001 an order under another contract?
Yes. 75N92B21F00001 is a BPA call under HHSN263201500148B, a blanket purchase agreement.
Was contract 75N92B21F00001 competed?
The extent of competition for 75N92B21F00001 was competed under sap. The government received 3 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award